The Efficacy of Combination Therapy Using Adeno-associated Virus-TRAIL Targeting to Telomerase Activity and Cisplatin in a Mice Model of Hepatocellular Carcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2010 Mar 10

PMID 20213096

Citations 18

Authors

Yigang Wang

Fang Huang

Haibo Cai

Yumei Wu

Guoqing He

Wen-Song Tan

Affiliations

Soon will be listed here.

Abstract

Purpose: TNF-related apoptosis-inducing ligand (TRAIL) functions as a soluble cytokine and has been demonstrated significant antitumor activity against a variety of cancer cell lines without toxicity to most normal cells. Cisplatin is a potent anticancer agent and is widely used in the clinical for treatment of human cancers. Adeno-associated virus (AAV2) is a promising gene delivery vehicle for its advantage of low pathogenicity and long-term gene expression. However, lack of tissue specificity caused low efficiency of AAV transfer to target cells. The promoter of human telomerase reverse transcriptase (hTERT) is a good candidate to enhance targeting efficiency of AAV in cancer cells. Although AAV-mediated TRAIL controlled by hTERT promoter (AAV-hTERT-TRAIL) has obvious antitumor activity, the tumor cannot be completely eradicated. In this study, we first examined the effectiveness of combination therapy of cisplatin and AAV-hTERT-TRAIL on human hepatocellular carcinoma (HCC) in vitro and in vivo.

Methods: For in vitro experiments, tumor cell lines were treated with cisplatin, virus, or both. The transgene TRAIL expression controlled by hTERT promoter was evaluated in BEL7404 HCC cell line. Cytotoxicity was performed by MTT analysis. Cell apoptosis was detected by flow cytometry analysis. The in vivo antitumor efficacy of combination treatment with cisplatin and AAV-hTERT-TRAIL was assessed in human hepatocellular carcinoma xenografts mouse model.

Results: The enhanced TRAIL expression was observed in BEL7404 cells treated with AAV-hTERT-TRAIL plus cisplatin. Treatment with both AAV-hTERT-TRAIL and cisplatin exhibited stronger cytotoxicity and induced more significant apoptosis in cancer cells compared with AAV-hTERT-TRAIL or cisplatin alone, respectively. Moreover, in animal experiments, the combined treatment greatly suppressed tumor growth and resulted in tumor cell death.

Conclusions: AAV-mediated therapeutic gene expression in combination with chemotherapy provides a promising therapeutic strategy for human cancers. These data suggest that combined use of AAV-hTERT-TRAIL and cisplatin may have potential clinical application.

Citing Articles

Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.

Hadi M, Allela O, Jabari M, Jasoor A, Naderloo O, Yasamineh S Virol J. 2024; 21(1):17.

PMID: 38216938 PMC: 10785434. DOI: 10.1186/s12985-024-02286-1.

Adding recombinant AAVs to the cancer therapeutics mix.

Mulcrone P, Herzog R, Xiao W Mol Ther Oncolytics. 2022; 27:73-88.

PMID: 36321134 PMC: 9588955. DOI: 10.1016/j.omto.2022.09.009.

Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors.

Meumann N, Schmithals C, Elenschneider L, Hansen T, Balakrishnan A, Hu Q Cancers (Basel). 2022; 14(2).

PMID: 35053588 PMC: 8774135. DOI: 10.3390/cancers14020427.

A Titanium (IV)-Dithiophenolate Complex and Its Chitosan Nanocomposite: Their Roles towards Rat Liver Injuries In Vivo and against Human Liver Cancer Cell Lines.

Shaban N, Yehia S, Awad D, Shaban S, Saleh S Int J Mol Sci. 2021; 22(20).

PMID: 34681878 PMC: 8540501. DOI: 10.3390/ijms222011219.

Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy.

Bower J, Song L, Bastola P, Hirsch M Viruses. 2021; 13(7).

PMID: 34201599 PMC: 8309980. DOI: 10.3390/v13071205.

References

Shin M, Kim H, Lee S, Park W, Kim S, Park J . Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 2001; 61(13):4942-6. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Lee S, Shin M, Kim H, Lee H, Park W, Kim S . Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 1999; 59(22):5683-6. View

Liu J, Zou W, Lang M, Luo J, Sun L, Wang X . Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int J Oncol. 2002; 21(3):661-6. View

Keane M, Ettenberg S, Nau M, RUSSELL E, Lipkowitz S . Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999; 59(3):734-41. View

Wohlfahrt M, Beard B, Lieber A, Kiem H . A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res. 2007; 67(18):8783-90. DOI: 10.1158/0008-5472.CAN-07-0357. View

Pitti R, Marsters S, Ruppert S, Donahue C, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271(22):12687-90. DOI: 10.1074/jbc.271.22.12687. View

Adam M, Bayer C, Henke J, Grosu A, Molls M, Nieder C . Tirapazamine plus cisplatin and irradiation in a mouse model: improved tumor control at the cost of increased toxicity. J Cancer Res Clin Oncol. 2007; 134(2):137-46. DOI: 10.1007/s00432-007-0260-7. View

Vandenberghe L, Wilson J . AAV as an immunogen. Curr Gene Ther. 2007; 7(5):325-33. DOI: 10.2174/156652307782151416. View

10.

Zaiss A, Muruve D . Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 2008; 15(11):808-16. DOI: 10.1038/gt.2008.54. View

11.

Shi J, Zheng D, Liu Y, Sham M, Tam P, Farzaneh F . Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 2005; 65(5):1687-92. DOI: 10.1158/0008-5472.CAN-04-2749. View

12.

Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C . Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem. 2007; 304(1-2):315-23. DOI: 10.1007/s11010-007-9514-6. View

13.

Pan Q, Zhong S, Liu B, Liu J, Cai R, Wang Y . Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Acta Pharmacol Sin. 2007; 28(12):1996-2004. DOI: 10.1111/j.1745-7254.2007.00672.x. View

14.

Lin T, Huang X, Gu J, Zhang L, Roth J, Xiong M . Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene. 2002; 21(52):8020-8. DOI: 10.1038/sj.onc.1205926. View

15.

Chinnaiyan A, Prasad U, Shankar S, Hamstra D, Shanaiah M, Chenevert T . Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000; 97(4):1754-9. PMC: 26508. DOI: 10.1073/pnas.030545097. View

16.

Arany I, Safirstein R . Cisplatin nephrotoxicity. Semin Nephrol. 2003; 23(5):460-4. DOI: 10.1016/s0270-9295(03)00089-5. View

17.

Voelkel-Johnson C, King D, Norris J . Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002; 9(2):164-72. DOI: 10.1038/sj.cgt.7700420. View

18.

Armeanu S, Lauer U, Smirnow I, Schenk M, Weiss T, Gregor M . Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 2003; 63(10):2369-72. View

19.

Muzio M, Chinnaiyan A, Kischkel F, ORourke K, Shevchenko A, Ni J . FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell. 1996; 85(6):817-27. DOI: 10.1016/s0092-8674(00)81266-0. View

20.

Wang X, Su C, Cao H, Li K, Chen J, Jiang L . A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol Cancer Ther. 2008; 7(6):1598-603. DOI: 10.1158/1535-7163.MCT-07-2429. View